This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, Y. Articles by Weissman, A. M. Search for Related Content PubMed PubMed Citation Articles by Yang, Y. Articles by Weissman, A. M.

Inhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics

¹ Laboratory of Protein Dynamics and Signaling, ² Laboratory of Cancer Prevention, and ³ Molecular Targets Development Program, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, Maryland; ⁴ The Beatson Institute for Cancer Research, Glasgow, United Kingdom; and ⁵ Meso Scale Discovery, Gaithersburg, Maryland

Requests for reprints: Allan M. Weissman or Yili Yang, Laboratory of Protein Dynamics and Signaling, Building 560 Room 22-103, 560 Boyles Street, Frederick, MD 21702. Phone: 301-846-1222; Fax: 301-846-1666; E-mail: amw{at}nih.gov or yangyili{at}ncifcrf.gov.

The conjugation of proteins with ubiquitin plays numerous regulatory roles through both proteasomal-dependent and nonproteasomal-dependent functions. Alterations in ubiquitylation are observed in a wide range of pathologic conditions, including numerous malignancies. For this reason, there is great interest in targeting the ubiquitin-proteasome system in cancer. Several classes of proteasome inhibitors, which block degradation of ubiquitylated proteins, are widely used in research, and one, Bortezomib, is now in clinical use. Despite the well-defined and central role of the ubiquitin-activating enzyme (E1), no cell permeable inhibitors of E1 have been identified. Such inhibitors should, in principle, block all functions of ubiquitylation. We now report 4[4-(5-nitro-furan-2-ylmethylene)-3,5-dioxo-pyrazolidin-1-yl]-benzoic acid ethyl ester (PYR-41) as the first such inhibitor. Unexpectedly, in addition to blocking ubiquitylation, PYR-41 increased total sumoylation in cells. The molecular basis for this is unknown; however, increased sumoylation was also observed in cells harboring temperature-sensitive E1. Functionally, PYR-41 attenuates cytokine-mediated nuclear factor-B activation. This correlates with inhibition of nonproteasomal (Lys-63) ubiquitylation of TRAF6, which is essential to IB kinase activation. PYR-41 also prevents the downstream ubiquitylation and proteasomal degradation of IB. Furthermore, PYR-41 inhibits degradation of p53 and activates the transcriptional activity of this tumor suppressor. Consistent with this, it differentially kills transformed p53-expressing cells. Thus, PYR-41 and related pyrazones provide proof of principle for the capacity to differentially kill transformed cells, suggesting the potential for E1 inhibitors as therapeutics in cancer. These inhibitors can also be valuable tools for studying ubiquitylation. [Cancer Res 2007;67(19):9472–81]

This article has been cited by other articles:

				T. Ueki, J.-H. Park, T. Nishidate, K. Kijima, K. Hirata, Y. Nakamura, and T. Katagiri Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer Cells Cancer Res., November 15, 2009; 69(22): 8752 - 8760. [Abstract] [Full Text] [PDF]

				J. Herrmann, L. O. Lerman, and A. Lerman On to the road to degradation: atherosclerosis and the proteasome Cardiovasc Res, November 14, 2009; (2009) cvp333v2. [Abstract] [Full Text] [PDF]

				A. Sen, N. Feng, K. Ettayebi, M. E. Hardy, and H. B. Greenberg IRF3 Inhibition by Rotavirus NSP1 Is Host Cell and Virus Strain Dependent but Independent of NSP1 Proteasomal Degradation J. Virol., October 15, 2009; 83(20): 10322 - 10335. [Abstract] [Full Text] [PDF]

				L. Mi, N. Gan, A. Cheema, S. Dakshanamurthy, X. Wang, D. C. H. Yang, and F.-L. Chung Cancer Preventive Isothiocyanates Induce Selective Degradation of Cellular {alpha}- and {beta}-Tubulins by Proteasomes J. Biol. Chem., June 19, 2009; 284(25): 17039 - 17051. [Abstract] [Full Text] [PDF]

				D. L. Hodge, J. Yang, M. D. Buschman, P. M. Schaughency, H. Dang, W. Bere, Y. Yang, R. Savan, J. J. Subleski, X.-M. Yin, et al. Interleukin-15 Enhances Proteasomal Degradation of Bid in Normal Lymphocytes: Implications for Large Granular Lymphocyte Leukemias Cancer Res., May 1, 2009; 69(9): 3986 - 3994. [Abstract] [Full Text] [PDF]

				P. S. Satheshkumar, L. C. Anton, P. Sanz, and B. Moss Inhibition of the Ubiquitin-Proteasome System Prevents Vaccinia Virus DNA Replication and Expression of Intermediate and Late Genes J. Virol., March 15, 2009; 83(6): 2469 - 2479. [Abstract] [Full Text] [PDF]

				A. Teale, S. Campbell, N. Van Buuren, W. C. Magee, K. Watmough, B. Couturier, R. Shipclark, and M. Barry Orthopoxviruses Require a Functional Ubiquitin-Proteasome System for Productive Replication J. Virol., March 1, 2009; 83(5): 2099 - 2108. [Abstract] [Full Text] [PDF]

				M. Wade and G. M. Wahl Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? Mol. Cancer Res., January 1, 2009; 7(1): 1 - 11. [Abstract] [Full Text] [PDF]